Orchard Therapeutics plc
ORTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1,346.4% | -81.4% | 3.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 65.2% | 53.2% | 67% | 68% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -115.6% | -7,358.4% | -5,717.8% | -6,182.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -112.8% | -7,525.7% | -5,856.6% | -6,503.1% |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 |
| % Growth | 79.2% | 80.8% | 12.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |